| | | |
| Breast |
NCT06112379
D926QC00001, 2023-505928-59-00 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Dr. David Cescon | Breast |
NCT06103864
D7630C00001 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Dr. David Cescon | Breast |
NCT05417516
OCOG-2022-RAPID2 | A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) | Dr. Jennifer Croke | Breast |
NCT06312176
2870-010, MK-2870-010,2023-504918-29-00,U1111-1289-8119,jRCT2031240476 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Dr. David Cescon | Breast |
NCT06065748
CO44657, 2022-502980-39-00 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Dr. Vikaash Kumar | Breast |
NCT06206837
C4891026, TACTIVE-K,2023-508130-33-00 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | Dr. David Cescon | Breast |
NCT01837225
10-0633-CE | ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI and Eagle Imaging Devices | Dr. Wey Leong | Breast |
NCT04397185
BCL IDE | Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer | Dr. Wey Leong | Breast |
NCT02306538
13-6543C | Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI | Dr. Dinesh Thavendiranathan | Breast |
NCT04228991
OCOG-2019-RHEAL | Hypofractionated LocoRegional Radiotherapy in Breast Cancer | Dr. Kathy Han | Breast |
NCT06710197
WOO-11-2023 | IL-1 Inhibition in Early TNBC | Dr. Michael Reedijk | Breast |
NCT05388149
22-5307, KAN-HER2 MRD | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | Dr. David Cescon | Breast |
NCT05601440
I241 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | Dr. David Cescon | Breast |
NCT05592938
22-5074 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) | Dr. Danielle Rodin | Breast |
NCT05812807
A012103, NCI-2022-07859 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Dr. David Cescon | Breast |
NCT03564171
041-2018 | Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer | Dr. Daniel Santa Mina | Breast |
NCT04874038
21-5021 | Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) | Dr. Hance Clarke | Breast |
NCT04797299
OCOG-2021-ELISA | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) | Dr. Ezra Hahn | Breast |
NCT03488693
CCTG MA.39, NCI-2017-02047 | Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Dr. Christine Koch | Breast |
NCT06393374
2870-012, 2023-504962-52-00,U1111-1289-8264,jRCT2031240476 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Dr. David Cescon | Breast |
